Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
Abstract Background Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab. Methods...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02295-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594929061199872 |
|---|---|
| author | Ronghui Li Haibo Lei Chunjiang Wang Xiang Liu |
| author_facet | Ronghui Li Haibo Lei Chunjiang Wang Xiang Liu |
| author_sort | Ronghui Li |
| collection | DOAJ |
| description | Abstract Background Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab. Methods We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024. Results A total of forty patients (21 males and 19 females) fulfilled the inclusion criteria, with a median age of 42 years (range 19, 70). The median time to IBD onset was 4 months following the initial dose (range 0.25, 53). The most common symptoms reported were abdominal pain (60.0%), diarrhea (37.5%), bloody diarrhea (32.5%), and fever (30.0%). Colonoscopy findings predominantly showed ulcers (62.5%) and inflammation (27.5%). Biopsy results revealed crypt microabscesses (22.5%), cryptitis (20.0%), inflammatory cellular infiltrates (20.0%), and both acute and chronic inflammation (22.5%). After discontinuation of secukinumab, patients reported symptom relief following treatment with systemic steroids (60.0%), targeted therapies (52.5%), and mesalamine (22.5%). Conclusions Comprehensive screenings are essential for patients prior to initiating secukinumab therapy. Gastrointestinal symptoms necessitate close monitoring during secukinumab treatment. Upon the diagnosis of IBD, secukinumab should be discontinued, and systemic steroid therapy should be initiated. Patients who do not respond or experience a relapse should be considered for immunosuppressive therapy. |
| format | Article |
| id | doaj-art-b9ea985fdd864250b468f52aae2cb70e |
| institution | Kabale University |
| issn | 2047-783X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj-art-b9ea985fdd864250b468f52aae2cb70e2025-01-19T12:14:57ZengBMCEuropean Journal of Medical Research2047-783X2025-01-013011710.1186/s40001-025-02295-yClinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel diseaseRonghui Li0Haibo Lei1Chunjiang Wang2Xiang Liu3Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university)Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university)Department of Pharmacy, The Third Xiangya Hospital, Central South UniversityDepartment of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university)Abstract Background Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab. Methods We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024. Results A total of forty patients (21 males and 19 females) fulfilled the inclusion criteria, with a median age of 42 years (range 19, 70). The median time to IBD onset was 4 months following the initial dose (range 0.25, 53). The most common symptoms reported were abdominal pain (60.0%), diarrhea (37.5%), bloody diarrhea (32.5%), and fever (30.0%). Colonoscopy findings predominantly showed ulcers (62.5%) and inflammation (27.5%). Biopsy results revealed crypt microabscesses (22.5%), cryptitis (20.0%), inflammatory cellular infiltrates (20.0%), and both acute and chronic inflammation (22.5%). After discontinuation of secukinumab, patients reported symptom relief following treatment with systemic steroids (60.0%), targeted therapies (52.5%), and mesalamine (22.5%). Conclusions Comprehensive screenings are essential for patients prior to initiating secukinumab therapy. Gastrointestinal symptoms necessitate close monitoring during secukinumab treatment. Upon the diagnosis of IBD, secukinumab should be discontinued, and systemic steroid therapy should be initiated. Patients who do not respond or experience a relapse should be considered for immunosuppressive therapy.https://doi.org/10.1186/s40001-025-02295-ySecukinumabInflammatory bowel diseaseIndeterminate colitisCrohn's diseaseUlcerative colitis |
| spellingShingle | Ronghui Li Haibo Lei Chunjiang Wang Xiang Liu Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease European Journal of Medical Research Secukinumab Inflammatory bowel disease Indeterminate colitis Crohn's disease Ulcerative colitis |
| title | Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease |
| title_full | Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease |
| title_fullStr | Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease |
| title_full_unstemmed | Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease |
| title_short | Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease |
| title_sort | clinical features treatment and prognosis of secukinumab induced inflammatory bowel disease |
| topic | Secukinumab Inflammatory bowel disease Indeterminate colitis Crohn's disease Ulcerative colitis |
| url | https://doi.org/10.1186/s40001-025-02295-y |
| work_keys_str_mv | AT ronghuili clinicalfeaturestreatmentandprognosisofsecukinumabinducedinflammatoryboweldisease AT haibolei clinicalfeaturestreatmentandprognosisofsecukinumabinducedinflammatoryboweldisease AT chunjiangwang clinicalfeaturestreatmentandprognosisofsecukinumabinducedinflammatoryboweldisease AT xiangliu clinicalfeaturestreatmentandprognosisofsecukinumabinducedinflammatoryboweldisease |